查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1790417

红色生物技术市场规模、份额和趋势分析报告：按产品、最终用途、地区和细分市场预测，2025 年至 2030 年

Red Biotechnology Market Size, Share & Trends Analysis Report By Product, By End Use (Academic Research Institutes, CMOs & CROs, Pharmaceutical & Biotechnology Companies, Others), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10个工作天内

价格

红色生物技术市场摘要

2024 年全球红色生物技术市场价值估计为 5,465.9 亿美元，预计到 2030 年将达到 9,977.4 亿美元，2025 年至 2030 年期间的复合年增长率为 10.5%。个人化医疗需求的不断增长、对生物技术产品研究的高投入以及基因研究的进步正在塑造该行业。

红色生物技术涉及生物技术应用，例如干细胞、基因治疗、基因工程以及新药和疫苗的开发。红色生物技术是利用生物体改善医疗保健并帮助人体抵抗疾病的过程。它是现代医学技术的一部分。它在製药业和医疗领域的应用源于其减轻人类痛苦和改善生活品质的潜力。越来越多地使用基因工程来生产生物药物是一个主要趋势。这涉及使用重组DNA技术来创建能够批量生产特定蛋白质（例如治疗性抗体）的转基因生物。

预计市场在预测期内将经历良好成长。疾病管理方面已经取得了重大进展，从治疗急性微生物感染疾病的抗生素到抗爱滋病毒/爱滋病药物等慢性疾病，包括有助于控制爱滋病的迭氮胸苷。许多製药公司正在开发和生产用于治疗糖尿病和阿兹海默症和帕金森氏症等神经系统疾病的在研发线产品。根据clinicaltrials.gov的数据，截至 2021 年 1 月，有 126 种药物正在进行治疗阿兹海默症的临床试验，其中 28 种正处于 III 期试验阶段。发酵技术广泛应用于生命科学和医疗保健领域，对市场成长产生了积极影响。

这个市场持续成长，并具有加速医学进步和改变遗传性疾病识别方式的巨大潜力。新的检测方法可以检测出疾病相关基因DNA序列的变化，而早期检测对于透过早期治疗预防或减缓疾病进展至关重要。

目录

第一章调查方法与范围

第二章执行摘要

第三章红色生物技术市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 红色生物技术市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
  • 红色生物技术市场：通路分析

第四章红色生物技术市场：产品估计与趋势分析

  • 产品细分仪表板
  • 红色生物技术市场：产品差异分析
  • 全球红色生物技术市场规模与趋势分析（按产品，2018-2030 年）
  • 单株抗体
  • 多株抗体
  • 重组蛋白
  • 疫苗
  • 细胞免疫疗法产品
  • 基因治疗产品
  • 细胞治疗产品
  • 组织工程产品
  • 干细胞
  • 细胞培养
  • 病毒载体
  • 酵素
  • 套件和试剂
  • 动物模型
  • 分子诊断
  • 其他的

第五章红色生物技术市场：最终用途估计与趋势分析

  • 最终用途细分仪表板
  • 红色生物技术市场：最终用途差异分析
  • 全球红色生物技术市场规模和趋势分析（按最终用途，2018-2030 年）
  • 学术研究机构
  • CMO和CRO
  • 製药和生物技术公司
  • 其他的

第六章红色生物技术市场：区域估计与趋势分析

  • 区域市场仪表板
  • 2024 年及 2030 年区域市场占有率分析
  • 红色生物技术市场（按地区）: 关键要点
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • Key company heat map analysis, 2024
  • 公司简介
    • Merck KGaA
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Gilead Sciences, Inc.
    • Biogen
    • Amgen Inc.
    • Celgene Corporation（acquired by Bristol-Myers Squibb Company）
Product Code: GVR-4-68040-042-9

Red Biotechnology Market Summary

The global red biotechnology market size was estimated at USD 546.59 billion in 2024, and is projected to reach USD 997.74 billion by 2030, growing at a CAGR of 10.5% from 2025 to 2030. The increasing demand for personalized medicine, high investment in the R&D of biotechnology products, and advances in genetic research are shaping the field.

Red biotechnology deals with biotechnological applications such as stem cells, gene therapy, genetic engineering, and the development of new drugs and vaccines. Red biotechnology is a process that uses organisms to improve health care and aid the body in fighting diseases. It is a subset of modern technology used in the field of medicine. It finds application in the pharmaceutical industry and the medical sector, as it helps alleviate human suffering and improves the quality of life. The increasing usage of genetic engineering to produce biological medicine is one of the major trends. This includes using recombinant DNA technology to create genetically modified organisms capable of producing large amounts of a specific protein, such as a therapeutic antibody.

The market is expected to witness lucrative growth during the forecast period. It has made significant advancements in disease control, from antibiotics for treating acute microbial infections to chronic conditions such as anti-HIV/AIDS, including azidothymidine, which has helped manage AIDS. Many pharmaceutical companies are developing and manufacturing pipeline products for diabetes and neurological disorders such as Alzheimer's and Parkinson's disease. According to clinicaltrials.gov, 126 agents were in clinical trials for the treatment of Alzheimer's disease as of January 2021, with 28 treatments in phase III trials. Fermentation technology is widely used in the life sciences and healthcare sectors, positively impacting market growth.

The market is still growing, with significant potential for driving medical advancements and transforming the identification of diseases caused by genetic factors. Novel tests can detect changes in the DNA sequence of genes linked to diseases, and early detection is a crucial factor in avoiding disease or slowing its progression through early treatment.

Global Red Biotechnology Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global red biotechnology market report based on product, end-use, and region:

  • Product Outlook (Revenue, USD Billion, 2018 - 2030)
  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Cell-Based Immunotherapy Products
  • Gene Therapy Products
  • Cell Therapy Products
  • Tissue-Engineered Products
  • Stem Cells
  • Cell Culture
  • Viral Vector
  • Enzymes
  • Kits and Reagents
  • Animal models
  • Molecular diagnostics
  • Others
  • End-User Outlook (Revenue, USD Billion, 2018 - 2030)
  • Academic Research Institutes
  • CMOs & CROs
  • Pharmaceutical & Biotechnology Companies
  • Others
  • Regional Outlook (Revenue, USD Billion, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Red Biotechnology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Red Biotechnology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Red Biotechnology Market: Pipeline Analysis

Chapter 4. Red Biotechnology Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. Red Biotechnology Market: Product Movement Analysis
  • 4.3. Global Red Biotechnology Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Billion)
  • 4.4. Monoclonal Antibodies
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Polyclonal Antibodies
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.6. Recombinant Proteins
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.7. Vaccines
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.8. Cell-Based Immunotherapy Products
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.9. Gene Therapy Products
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.10. Cell Therapy Products
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.11. Tissue - Engineered Products
    • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.12. Stem Cells
    • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.13. Cell Culture
    • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.14. Viral Vector
    • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.15. Enzymes
    • 4.15.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.16. Kits and Reagents
    • 4.16.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.17. Animal Models
    • 4.17.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.18. Molecular Diagnostics
    • 4.18.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.19. Others
    • 4.19.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Red Biotechnology Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Segment Dashboard
  • 5.2. Red Biotechnology Market: End Use Movement Analysis
  • 5.3. Global Red Biotechnology Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
  • 5.4. Academic Research Institutes
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. CMOs & CROs
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Pharmaceutical & Biotechnology Companies
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.7. Others
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Red Biotechnology Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Red Biotechnology Market by Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Canada
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.3. Mexico
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.2. Germany
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.3. France
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.4. Italy
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.5. Spain
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.6. Norway
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.7. Sweden
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework/ reimbursement structure
      • 6.5.7.3. Competitive scenario
      • 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.8. Denmark
      • 6.5.8.1. Key country dynamics
      • 6.5.8.2. Regulatory framework/ reimbursement structure
      • 6.5.8.3. Competitive scenario
      • 6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.2. China
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.3. India
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.4. Australia
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.5. South Korea
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.6. Thailand
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.2. Argentina
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.3. UAE
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Regulatory framework/ reimbursement structure
      • 6.8.4.3. Competitive scenario
      • 6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company heat map analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Merck KGaA
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. F. Hoffmann-La Roche Ltd
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Pfizer Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Regeneron Pharmaceuticals, Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. AstraZeneca
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Takeda Pharmaceutical Company Limited
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Gilead Sciences, Inc.
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Biogen
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Amgen Inc.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Celgene Corporation (acquired by Bristol-Myers Squibb Company)
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiativesa

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global red biotechnology market, by region, 2018 - 2030 (USD Billion)
  • Table 3 Global red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 4 Global red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 5 North America red biotechnology market, by country, 2018 - 2030 (USD Billion)
  • Table 6 North America red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 7 North America red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 8 U.S. red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 9 U.S. red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 10 Canada red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 11 Canada red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 12 Mexico red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 13 Mexico red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 14 Europe red biotechnology market, by country, 2018 - 2030 (USD Billion)
  • Table 15 Europe red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 16 Europe red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 17 Germany red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 18 Germany red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 19 UK red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 20 UK red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 21 France red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 22 France red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 23 Italy red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 24 Italy red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 25 Spain red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 26 Spain red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 27 Denmark red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 28 Denmark red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 29 Sweden red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 30 Sweden red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 31 Norway red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 32 Norway red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 33 Asia Pacific red biotechnology market, by country, 2018 - 2030 (USD Billion)
  • Table 34 Asia Pacific red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 35 Asia Pacific red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 36 China red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 37 China red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 38 Japan red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 39 Japan red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 40 India red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 41 India red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 42 South Korea red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 43 South Korea red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 44 Australia red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 45 Australia red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 46 Thailand red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 47 Thailand red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 48 Latin America red biotechnology market, by country, 2018 - 2030 (USD Billion)
  • Table 49 Latin America red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 50 Latin America Academic research institutes market, by end use, 2018 - 2030 (USD Billion)
  • Table 51 Latin America red biotechnology market, by application, 2018 - 2030 (USD Billion)
  • Table 52 Brazil red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 53 Brazil red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 54 Argentina red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 55 Argentina red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 56 MEA red biotechnology market, by region, 2018 - 2030 (USD Billion)
  • Table 57 MEA red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 58 MEA red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 59 South Africa red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 60 South Africa red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 61 Saudi Arabia red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 62 Saudi Arabia red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 63 UAE red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 64 UAE red biotechnology market, by end use, 2018 - 2030 (USD Billion)
  • Table 65 Kuwait red biotechnology market, by product, 2018 - 2030 (USD Billion)
  • Table 66 Kuwait red biotechnology market, by end use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Red biotechnology market: market outlook
  • Fig. 10 Red biotechnology competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Red biotechnology market driver impact
  • Fig. 16 Red biotechnology market restraint impact
  • Fig. 17 Red biotechnology market strategic initiatives analysis
  • Fig. 18 Red biotechnology market: product movement analysis
  • Fig. 19 Red biotechnology market: product outlook and key takeaways
  • Fig. 20 Monoclonal antibodies market estimates and forecast, 2018 - 2030
  • Fig. 21 Polyclonal antibodies market estimates and forecast, 2018 - 2030
  • Fig. 22 Recombinant proteins market estimates and forecast, 2018 - 2030
  • Fig. 23 Vaccines market estimates and forecast, 2018 - 2030
  • Fig. 24 Cell-based immunotherapy products market estimates and forecast, 2018 - 2030
  • Fig. 25 Gene therapy products market estimates and forecast, 2018 - 2030
  • Fig. 26 Cell therapy products market estimates and forecast, 2018 - 2030
  • Fig. 27 Tissue - engineered products market estimates and forecast, 2018 - 2030
  • Fig. 28 Stem cells market estimates and forecast, 2018 - 2030
  • Fig. 29 Cell culture market estimates and forecast, 2018 - 2030
  • Fig. 30 Viral vector market estimates and forecast, 2018 - 2030
  • Fig. 31 Enzymes market estimates and forecast, 2018 - 2030
  • Fig. 32 Kits and reagents therapy market estimates and forecast, 2018 - 2030
  • Fig. 33 Animal models market estimates and forecast, 2018 - 2030
  • Fig. 34 Molecular diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 35 Others market estimates and forecast, 2018 - 2030
  • Fig. 36 Red biotechnology market: end use movement analysis
  • Fig. 37 Red biotechnology market: end use outlook and key takeaways
  • Fig. 38 Academic research institutes market estimates and forecasts, 2018 - 2030
  • Fig. 39 CMOs & CROs market estimates and forecasts,2018 - 2030
  • Fig. 40 Pharmaceutical & biotechnology companies market estimates and forecasts,2018- 2030
  • Fig. 41 Others market estimates and forecasts,2018 - 2030
  • Fig. 42 Global red biotechnology market: regional movement analysis
  • Fig. 43 Global red biotechnology market: regional outlook and key takeaways
  • Fig. 44 North America market estimates and forecasts, 2018 - 2030
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 46 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 47 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 48 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 49 UK market estimates and forecasts, 2018 - 2030
  • Fig. 50 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 51 France market estimates and forecasts, 2018 - 2030
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 53 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 54 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 55 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 56 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 57 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 58 China market estimates and forecasts, 2018 - 2030
  • Fig. 59 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 60 India market estimates and forecasts, 2018 - 2030
  • Fig. 61 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 62 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 63 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 64 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 65 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 66 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 67 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 68 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 69 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 70 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 71 Kuwait market estimates and forecasts, 2018 - 2030